Romosozumab Associated with Lower Osteoporotic Fracture Risk than Alendronate — Physician’s First Watch

Medical News |
September 12, 2017

Romosozumab Associated with Lower Osteoporotic Fracture Risk than Alendronate

By Joe Elia

Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD

Romosozumab outperformed alendronate in lowering osteoporosis-related fracture risk, according to an industry-conducted, phase 3 study published in the New England Journal of Medicine and presented at the American Society for Bone and Mineral Research's annual meeting. The investigational monoclonal antibody binds to sclerostin and prevents it from inhibiting bone formation.

Investigators studied some 4100 women with osteoporosis and a history of fragility fracture. They were randomized to 12 months' treatment with either romosozumab or alendronate; both treatments were followed by open-label alendronate.

At the 24-month mark, the risk for new vertebral fracture was 6.2% in the romosozumab-to-alendronate group, versus 11.9% in the alendronate-to-alendronate group. Similarly, risk for clinical fracture was lower with romosozumab than alendronate (9.7% vs. 13.0%).

Cardiovascular adverse events during the first 12 months of treatment were more common with romosozumab (2.5%) than with alendronate (1.9%).

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.